10:00 am - 12:00 pm CT |
EDUCATIONAL SESSION BLOCK #1 |
|
EDUCATIONAL SESSION BLOCK #1A - Stars at Night Ballroom 3&4
Living with Metastatic Breast Cancer
Moderator: Anne Blaes, MD, MSc
University of Minnesota
Minneapolis, MN
Early palliative care
Tara L. Kaufmann, MD, MSCE
Dell Medical School
University Of Texas at Austin
Austin, TX
Support for patients with MBC
Abbey Kaler, NP
UT MD Anderson Cancer Center
Houston, TX
Financial Toxicity
Fumiko Chino, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Patient Perspective
Christine Hodgdon, MS
GRASP - Guiding Researchers & Advocates to Scientific Partnerships
Baltimore, MD
Stephanie Walker, BSN
MBC Alliance
Tarboro, NC
EDUCATIONAL SESSION BLOCK #1B - Hemisfair Ballroom 1&2
Local Therapy - Best Breast Practice
Moderator: Peter Dubsky, MD, PhD
Breast Center Hirslanden Klinik St. Anna
Luzem, Switzerland
Contralateral mastectomy in patients with germline mutations
Katharine A. Yao, MD
Northshore University HealthSystem
Evanston, IL
RT: How short can it be
David Krug, Dr Med
Universitätsklinikum Schleswig-Holstein
Kiel, Germany
How to reconcile novel reconstructive techniques with the need to radiate
Christine Solbach, MD, PhD
University Hospital Frankfurt
Frankfurt, Germany
EDUCATIONAL SESSION BLOCK #1C - Hemisfair Ballroom 3
New Agents Targeting HRD in Breast Cancer
Moderator: Erica Stringer-Reasor, MD
University of Alabama at Birmingham
Birmingham, AL
Pol-theta inhibitors in HRD tumors
Alan D. d'Andrea, MD
Dana-Farber Cancer Institute
Boston, MA
Mechanisms of sensitivity and resistance to HRD targeting agents in breast cancer - PARPi and beyond
Christopher Lord, DPhil
Institute of Cancer Research
London, United Kingdom
ATR inhibitors and PARP1 selective PARP inhibitors
Andrew Tutt, MB ChB, PhD
Institute of Cancer Research
London, United Kingdom
EDUCATIONAL SESSION BLOCK #1D - Stars at Night Ballroom 1&2
Predictive Value of Treatment Response and Residual Disease After Neoadjuvant Therapy
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Hormone receptor positive breast cancer
Cynthia X. Ma, MD, PhD
Washington University in St. Louis
St. Louis, MO
HER2 positive breast cancer
Luca Gianni, MD
Fondazione Michelangelo
Milano, Italy
Triple negative breast cancer
Peter Schmid, MD, PhD, FRCP
Bart's Cancer Institute
London, United Kingdom
|
12:00 pm - 2:00 pm CT |
SPECIAL SESSION #1 - Stars at Night Ballroom 1&2
Big Data and Health Equity
Moderators: Thelma Brown, BSc
University of Alabama at Birmingham
Birmingham, AL
Maimah Karmo, BS
Tigerlily Foundation
Aldie, VA
Charles Perou, PhD
University of North Carolina
Chapel Hill, NC
Keynote Speakers:
Martin Mendoza, PhD
National Institutes of Health
Bethesda, MD
Barbara Seggara, D.H.Sc
University of Puerto Rico
San Juan, Puerto Rico
Panelists:
Rea Blakey
FDA
Silver Spring, MD
Thelma Perry Brown, BSc
University of Alabama at Birmingham
Birmingham, AL
Andrea Downing
The Light Collective
Shoreline, WA
Michael Crawford, MBA, MHLA
Howard University
Washington, DC
Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN
Martin Mendoza, PhD
National Institute of Health
Bethesda, MD
Charlotte Owens, MD
Takeda Pharmaceutical Company
Cambridge, MA
Barbara Seggara, D.H.Sc
University of Puerto Rico
San Juan, Puerto Rico
Jasmine Souers, BSc
The Missing Pink Breast Cancer Alliance
Jackson, FL
SPECIAL SESSION #2 - Hall 3
Overcoming the Big Obstacles to Find Solutions for Breast Cancer
Chairs:
Carlos Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
and
Angela DeMichele, MD, MSCE
University of Pennsylvania Abramson Cancer Center
Philadelphia, PA
Panelists:
Christine Ambrosone, PhD
Roswell Park Comprehensive Cancer Center
Buffalo, NY
Fabrice André, MD, PhD
Gustave Gustave Roussy
Villejuif, France
Regina Barzilay, PhD
Massachusetts Institute of Technology
Cambridge, MA
Joan S. Brugge, PhD
Harvard Ludwig Cancer Center
Boston, MA
Matthew J. Ellis, MD, PhD
AstraZeneca
Washington, DC
Nadia Harbeck, MD, PhD
LMU University Hospital
Munich, Germany
Yeon Hee Park, MD, PhD
Samsung Medical Center
Seoul, South Korea
Lori Pierce, MD
University of Michigan
Ann Arbor, MI
Patty Spears, BS
University of North Carolina at Chapel Hill
Chapel Hill, NC
Eric Winer, MD
Yale Cancer Center
New Haven, CT
|
2:00 pm - 5:00 pm CT |
GENERAL SESSION #1 - Hall 3 |
5:00 pm - 6:15 pm |
POSTER SESSION #1 - Hall 1 |
5:00 pm - 6:15 pm |
SPOTLIGHT POSTER DISCUSSION SESSION #1 Racial Outcomes and Disparities - Hemisfair Ballroom 1&2
SPOTLIGHT POSTER DISCUSSION SESSION #2 Tumor Immunology and Novel Immune Therapy Strategies - Stars at Night Ballroom 1&2
SPOTLIGHT POSTER DISCUSSION SESSION #3 New Radiation Techniques - Stars at Night Ballroom 3&4 |
|
OPEN SATELLITE EVENTS - Marriott Rivercenter
|
7:00 pm - 9:00 pm |
Clarifying the Complexities and Augmenting the Options in the Treatment of HR+/HER2- Breast Cancer: How to Build Better Skills to Make the Most of Existing and Emerging Therapies for the Benefit of Patients With HR+/HER2- MBC and EBC presented by PVI, PeerView Institute for Medical Education
|
7:00 pm |
Expanding the Spectrum of HER2-Positivity for Precision Breast Cancer Care:Clinical Implications of HER2-Low Status presented by Clinical Care Options,LLC |
7:00 pm |
Medical Crossfire®: Clinical Decision Making Under New Paradigms for HR+/HER2-Breast Cancer presented by Physicians' Education Resource, LLC
|
|
|
Wednesday, December 7
|
7:00 am - 8:15 am |
POSTER SESSION #2 - Hall 1
|
7:00 am - 8:15 am |
SPOTLIGHT POSTER DISCUSSION SESSION #4 Single Cell Approaches for Translational Research and Biomarker Discovery - Hemisfair Ballroom 1&2
SPOTLIGHT POSTER DISCUSSION SESSION #5 Advances in TNBC Biology - Stars at Night Ballroom 3&4
SPOTLIGHT POSTER DISCUSSION SESSION #6 Special Populations: Male Breast Cancer/Geriatrics - Stars at Night Ballroom 1&2
|
8:30 am - 9:00 am |
WILLIAM L. MCGUIRE MEMORIAL LECTURE - Hall 3
Leveraging Preclinical Models for Translational Breast Cancer Research
Jeffrey Rosen, PhD
Baylor College of Medicine
Houston, TX |
9:00 am - 9:45 am CT |
GENERAL SESSION #2 - Hall 3 |
9:45 am - 11:00 am CT |
HER2 Low: A Separate Entity? Special Session - Hall 3
Chairs: Adam Brufsky, MD, PhD
University of Pittsburgh
Pittsburgh, PA
and
Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL
PRO
Giuseppe Curigliano, MD, PhD
IEO Istituto Europeo di Oncologia
Milano, Italy
Con
Sara Tolaney, MD
Dana-Farber Cancer Institute
Boston, MA
|
10:00 am - 5:00 pm CT |
EXHIBITS - Hall 2 |
11:00 am - 12:00 pm CT |
MINI-SYMPOSIUM #1 - Hall 3
C. Kent Osborne HER2 and ER Crosstalk: Signaling Mechanisms and Clinical Implications Symposium
Moderator: Carlos Arteaga, MD
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
and
Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Special Guest: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX
Oncogene signal transduction and antiestrogen resistance
Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX
HER2 signaling the ER cistrome
Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, M
Treatment of ER+/HER2+ breast cancer
Stephen Johnston, MBBS
The Royal Marsden Hospital
London, United Kingdom
|
12:00 PM - 12:30 PM |
PLENARY LECTURE #1 - Hall 3
Lineage-defined Metabolism of Normal Mammary Cells and Origins of Cancer Metabolic Heterogeneity
Rama Khokha, PhD
University Health Network
Toronto, Canada |
12:30 pm - 1:00 pm |
AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH, supported by Aflac Inc. - Hall 3
Quantitative Medicine for Breast Cancer Patients
Charles M. Perou, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC |
12:30 pm - 1:30 pm CT |
CAREER DEVELOPMENT FORUM - Room 304
|
1:00 pm - 2:00 pm CT |
CLINICAL CASE DISCUSSION SESSION - Stars at Night Ballroom 1&2
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
Panelist:
Michael Gnant, MD, FACS, FEBShon
Medical University of Vienna
Vienna, Austria
Celina Kleer, MD
University of Michigan Medical School
Ann Arbor, MI
Julia Maues
GRASP
Washington, DC
George Sledge, Jr, MD
Stanford University
Stanford, CA
Jonathan Strauss, MD
Northwestern
Chicago, IL
|
1:00 pm - 2:00 pm CT |
FORUM #1 - Stars at Night Ballroom 3&4
Molecular Aspects of DCIS Progression
Moderator: E. Shelley Hwang, MD, MPH
Duke University
Durham, NC
Tumor stroma in DCIS progression
Robert West, MD, PhD
Stanford University Medical Center
Stanford, CA
Clonal evolution of DCIS to invasion
Jelle Wesseling, MD, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands
Defining clinical risk: How do we tailor therapy
Kimberly J. Van Zee, MS, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY
|
2:00 pm - 3:00 pm CT |
CLINICAL CONTROVERSIES - Hall 3
Moderator: Lisa Carey, MD, ScM, FASCO
UNC-Lineberger Comprehensive Cancer Center
Chapel Hill, NC
To clip or not to clip
Abigail Caudle, MD
UT MD Anderson Cancer Center
Houston, TX
and
Viviana E. Galimberti, MD, MPH
European Institute of Oncology
Milan, Italy
Duration of endocrine therapy
Kathryn Ruddy, MD, PhD
Mayo Clinic
Rochester, MN
and
Eleftherios (Terry) Mamounas, MD, MSc
Orlando Health Cancer Institute
Orlando, FL
Post Neoadjuvant therapy in TNBC
Heather McArthur, MD, MPH
UT Southwestern
Dallas, TX
and
Susan Domchek, MD
University of Pennsylvania School of Medicine
Philadelphia, PA
|
2:00 pm - 3:00 pm CT |
MINI-SYMPOSIUM #2 - Stars at Night Ballroom 1&2
Late Recurrence and Tumor Dormancy
Moderator: Alana Welm, PhD
Masonic Cancer Center
University of Minnesota
Minneapolis, MN
NK cells and dormancy
Isaac Chan, MD
UT Southwestern Medical Center
Dallas, TX
Extra cellular matrix and dormancy
Javier Bravo-Cordero, PhD
Icahn School of Medicine
New York, NY
Implications for clinical care
Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC
|
2:00 pm - 3:00 pm CT |
FORUM #2 New Targets and Strategies for Immunotherapy - Stars at Night Ballroom 3&4
Moderator: Justin Balko, PhD
Vanderbilt University Medical Center
Nashville, TN
Activating a collaborative innate-adaptive immune response to control metastasis
Mikala Egeblad, PhD
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY
Neutrophil elastase and anti-tumor effects
Lev Becker, PhD
University of Chicago
Chicago, IL
Immunosuppressive macrophages and PARP inhibitor resistance
Jennifer Guerriero, PhD
Brigham and Women's Hospital
Boston, MA
|
3:00 pm - 5:00 pm CT |
EDUCATIONAL SESSION BLOCK #2
EDUCATIONAL SESSION BLOCK #2A - Hemisfair Ballroom 1&2
Digital Health and PROs in Breast Cancer Research and Care
Moderator: Ann H. Partridge, MD, MPH
Dana Farber Institute
Boston, MA
What are PROs and evidence for benefit?
Shoshana Rosenberg, ScD, MPH
Weill Cornell Medicine
New York, NY
How to incorporate PROs into clinical care
Oluwadamilola "Lola" Fayanju, MD, MA, MPHS, FACS
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
Where are we going with digital interventions and PROs
Ines Vaz Luis, PhD
Gustave Roussy
Villejuif, France
Patient Advocate Perspective
Patty Spears, BS
UNC Patient Advocates for Research Council
Chapel Hill, NC
EDUCATIONAL SESSION BLOCK #2B - Stars at Night Ballroom 1&2
Antibody Drug Conjugates: Future Directions and Opportunities
Moderator: Ian E. Krop, MD, PhD
Yale School of Medicine
New Haven, CT
Bioengineering and mechanism of action of ADC
Puja Sapra, PhD
AstraZeneca
New York, NY
ADCs in breast oncology: Present and future
Shanu Modi, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Mechanisms of resistance
Leif Ellisen, MD, PhD
Massachusetts General Hospital
Boston, MA
EDUCATIONAL SESSION BLOCK #2C - Stars at Night Ballroom 3&4
Spatial and Single Cell Characterization of Breast Cancer - Progression
Moderator: Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA
Single cell profiling
Alex Swarbrick, PhD
Garvan Institute of Medical Research
Darlinghurst, Australia
Multiplex spatial proteomic profiling
David Rimm, MD, PhD
Yale University
New Haven, CT
Imaging mass cytometry of breast cancer
Raza Ali, MD, FRCPC, MSc
Cancer Research UK Cambridge Institute
Cambridge, United Kingdom
Beyond the lab: Clinical implications
Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA
EDUCATIONAL SESSION BLOCK #2D - Hemisfair Ballroom 3
Breast Cancer and Cardiovascular Toxicity: What an Oncologist Needs to Know
Moderators: Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO
and
Susan Dent, MD
Duke
Durham, NC
Beyond anthracyclines and trastuzumab: Cardiotoxicity of new novel agents
Susan Dent, MD
Duke
Durham, NC
Radiation therapy and cardiovascular disease in breast cancer
Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO
Cardiovascular toxicity and breast cancer: Detection and prevention strategies
Dinesh Thavendiranathan, MD, MSc
Peter Munk Cardiac Center, Toronto General Hospital, University of Toronto
Toronto, Canada
Perspective 1: Cardiac problems secondary to chemotherapy
Kiran Dhillon, PhD
UW Medicine
Seattle, WA
Perspective 2: Cardiac problems secondary to chemotherapy
Alexea Gaffney Adams, Dr. Med
Alexea Gaffney-Adams
New York, NY
|
5:00 pm - 6:15 pm CT |
POSTER SESSION #3 - Hall 1 |
5:00 pm - 6:15 pm CT |
SPOTLIGHT POSTER DISCUSSION SESSION #7 - Brain Metastasis - Stars at Night Ballroom 3&4
SPOTLIGHT POSTER DISCUSSION SESSION #8 - Symptom Management and Associated Toxicities - Stars at Night Ballroom 1&2
SPOTLIGHT POSTER DISCUSSION SESSION #9 - Immune Landscape and Microenvironments - Hemisfair Ballroom 1&2
|
|
OPEN SATELLITE EVENTS - Marriott Rivercenter |
7:00 pm |
Precision Medicine Advances in Early Breast Cancer: Experts Discuss the Expanding Role of Biomarkers to Guide Neo/Adjuvant Therapy presented by Clinical Care Options, LLC |
7:15 pm - 9:15 pm |
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast Cancer — An Independent Satellite Symposium Held in Conjunction with the 45th Annual San Antonio Breast Cancer Symposium presented by Research to Practice |
Thursday, December 8
|
7:00 am - 8:15 am CT |
POSTER SESSION #4 - Hall 1
|
7:00 am - 8:15 am CT |
SPOTLIGHT POSTER DISCUSSION SESSION #10 Endocrine Therapy and Resistance - Stars at Night Ballroom 3&4
SPOTLIGHT POSTER DISCUSSION SESSION #11 Improving Outcome for TNBC: New Directions in Immunotherapy - Stars at Night Ballroom 1&2
SPOTLIGHT POSTER DISCUSSION SESSION #12 Obesity and Breast Cancer- Hemisfair Ballroom 1&2
|
8:30 am - 11:00 am CT |
GENERAL SESSION #3 - Hall 3 |
10:00 am - 5:00 pm CT |
EXHIBITS - Hall 2 |
11:00 am - 12:00 pm CT |
DEBATE Are all of CDK4/6 Inhibitors the Same or Different?- Hall 3
|
12:00 pm - 12:30 pm CT |
PLENARY LECTURE #2 - Hall 3
Premenopausal ER+ Breast Cancer: Past, Present, and Future
Prudence Francis, MD
Peter MacCullum Cancer Centre
Victoria, Australia
|
12:30 pm - 1:00 pm CT |
BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN BASIC SCIENCE
Guardian at the Gates: Genome Stability, Cell State, Plasticity, and Breast Cancer
Geoffrey M. Wahl, PhD
Salk Institute for Biological Studies
La Jolla, CA |
1:00 pm - 2:00 pm CT |
MOLECULAR TUMOR BOARD - Stars at Night Ballroom 1&2
Moderator: Giuseppe Curigliano, MD, PhD
European Institute of Oncology
Milano, Italy
Panelist:
Philippe Bedard, MD
Princess Margaret Cancer Centre
Toronto, Canada
Amy L. Delson
University of California San Francisco
Atherton, CA
Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN
Sara Hurvitz, MD, FACP
University of California San Francisco
Los Angeles, CA
Antonio Marra, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Aleix Prat, MD, PhD
Hospital Clinic Barcelona
Barcelona, Spain
Daniel Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH
|
1:00 pm - 2:00 pm CT |
FORUM #3 - Stars at Night Ballroom 3&4
Modifying Tumor Response: Microbiome, Diet, and Fasting
Moderator: Sangeetha Reddy, MD, MSc
UT Southwestern Medical Center
Dallas, TX
Fungal regulation of breast tumor radiation response
Stephen L. Shiao, MD, PhD
Cedars-Sinai
Los Angeles, CA
Microbiome and response to immunotherapy
Jennifer A. Wargo, MD
UT MD Anderson Cancer Center
Houston, TX
Fasting and Microbiotic
Guido Kroemer, MD, PhD, PU-PH
University of Paris Descartes
Paris, France
|
2:00 pm - 3:00 pm CT |
TRANSLATIONAL CONTROVERSIES - Stars at Night Ballroom 1&2
Moderator: Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center
New York, NY
RIP MTD
Hope S. Rugo, MD, FASCO
University of California San Francisco
San Francisco, CA
Geoffrey Shapiro, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
Randomized trials vs real world evidence
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA
Sean Khozin, MD, MPH
CancerLinQ, LLC
New York, NY
Ki 67
Nadia Harbeck, MD, PhD
LMU University Hospital
Munich, Germany
Torsten Nielsen, MD, PhD, FRCPC
University of British Columbia
Vancouver, Canada
|
2:00 pm - 3:00 pm CT |
FORUM #4 - Stars at Night Ballroom 3&4
Demystifying CDKs in Breast Cancer: Beyond CDK4/6
Moderator: Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA
CDK4/6 inhibitor resistance: Biological mechanisms and novel approaches
Ariella Hanker, PhD
UT Southwestern Medical Center
Dallas, TX
Current status of CDK2 inhibitors in (pre-)clinical development
Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Inhibiting transcriptional CDKs in breast cancer
Charles Coombes, MD, PhD
Imperial College
London, United Kingdom
|
3:00 pm - 5:00 pm CT |
EDUCATIONAL SESSION BLOCK #3
EDUCATIONAL SESSION BLOCK #3A - Hemisfair Ballroom 1&2
Management of Hereditary Risk: Moderate-Risk Genes and New Approaches
Moderator: Seema A. Khan, MD
Northwestern University
Chicago, IL
Cancer risks in patients with moderate penetrance gene mutations
Payal D. Shah, MD
Penn Medicine
Philadelphia, PA
Screening for high-risk patients: Does everyone need annual MRI with mammogram?
Madeleine M.A. Tilanus-Linthorst, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands
Hormonal exposure and risk in BRCA1/2 carriers
Joanne Kotsopoulos, MSc, PhD
University of Toronto
Toronto, Canada
EDUCATIONAL SESSION BLOCK #3B - Stars at Night Ballroom 1&2
Challenging Types of Breast Cancer
Moderator: Bora Lim, MD
Baylor College of Medicine
Houston, TX
Pathologic aspects
Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Metaplastic
Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC
Inflammatory
Filipa Lynce, MD
Dana-Farber Cancer Institute
Boston, MA
Lobular/pleomorphic
Sibylle Loibl, MD, PhD
German Breast Group
Neu-isenburg, Germany
EDUCATIONAL SESSION BLOCK #3C - Stars at Night Ballroom 3&4
What ctDNA Can Tell Us
Moderator: Nicholas Turner, PhD, FRCP
The Royal Marsden Hospital
London, United Kingdom
Which is the best technique
Heather Parsons, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Can ctDNA substitute tissue testing
Ben O'Leary, MBBS, PhD
The Institute of Cancer Research
London, United Kingdom
Using ctDNA in detecting disease
Minetta C. Liu, MD
Natera
Austin, TX
|
5:00 pm - 6:15 pm CT |
POSTER SESSION #5 - Hall 1
SPOTLIGHT POSTER DISCUSSION SESSION #13 Therapeutic Approaches for HR+/Her2- Breast Cancer - Stars at Night Ballroom 1&2
SPOTLIGHT POSTER DISCUSSION SESSION #14 Breast Cancer Risk Modeling - Stars at Night Ballroom 3&4
SPOTLIGHT POSTER DISCUSSION SESSION #15 Local Regional/Management of the Axilla - Hemisfair Ballroom 1&2
|
|
OPEN SATELLITE EVENTS - Marriott Rivercenter |
7:00 pm - 8:45 pm |
Molecular Imaging and Breast Cancer: Selecting and Evaluating Targeted Treatments presented by Society of Nuclear Medicine and Molecular Imaging |
7:15 pm - 9:15 pm |
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer — An Independent Satellite Symposium Held in Conjunction with the 45th Annual San Antonio Breast Cancer Symposium presented by Research to Practice |
|
|
Friday, December 9
|
7:00 am - 8:15 am CT |
POSTER SESSION #6 - Hall 1
SPOTLIGHT POSTER DISCUSSION SESSION #16 Imaging to Diagnose Breast Cancer and Direct Its Treatment: Who, When, and How? - Hemisfair Ballroom 1&2
SPOTLIGHT POSTER DISCUSSION SESSION #17 Endocrine Therapy New Insights - Stars at Night Ballroom 1&2
SPOTLIGHT POSTER DISCUSSION SESSION #18 Updates and New Therapies for HER2 Positive Disease - Stars at Night Ballroom 3&4
|
8:30 am - 9:00 am CT |
AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH, supported by the Breast Cancer Research Foundation - Hall 3
Breast Cancer Prevention in Premenopausal Women: Accelerating Transition from Discoveries to Clinical Translation
Adetunji T. Toriola, MD, PhD, MPH
Washington University School of Medicine
St. Louis, MO |
9:00 AM - 11:30 AM CT |
GENERAL SESSION #4 - Hall 3 |
10:00 am - 5:00 pm CT |
EXHIBITS - Hall 2 |
11:30 am - 12:00 pm CT |
BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN CLINICAL RESEARCH
The Contribution of NSABP Clinical Trials to the Management of Early Breast Cancer: PAST AS PROLOGUE
Norman Wolmark, MD, FACS, FRCSC
University of Pittsburgh
Pittsburgh, PA
|
12:00 pm - 3:00 pm CT |
GENERAL SESSION #5 - Hall 3 |
3:00 pm - 5:00 pm CT |
EDUCATIONAL SESSION BLOCK #4
EDUCATIONAL SESSION BLOCK #4A - Stars at Night Ballroom 1&2
Advances in Pregnancy Associated Breast Cancer (PABC)
Moderator: Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL
Updates in the pathology of PABCS
Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL
Special treatment issues in this young patient population
Ann Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Oncofertility and other quality of life issues
Matteo Lambertini, MD, PhD
University of Genova - San Martino Hospital
Genova, Italy
EDUCATIONAL SESSION BLOCK #4B - Stars at Night Ballroom 3&4
State of the Art Radiotherapy: Reducing Toxicity and Increasing Options
Moderator: Wendy Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
Overview of the current state of the art - what patients and oncologists need to know
Rachel Jimenez, MD
Massachusetts General Hospital
Boston, MA
The role of advanced radiation technology in reducing toxicity
Melissa Mitchell, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
Evidence for ablative radiation in metastatic breast cancer
Chiaojung Jillian Tsai, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
EDUCATIONAL SESSION BLOCK #4C - Hemisfair Ballroom 1&2
Targeting the Tumor Microenvironment for Clinical Impact
Moderator: Diana Cittelly, PhD
University of Colorado Anschutz Medical Campus
Aurora, CO
Influence of bone microenvironment on metastasis
Igor Bado, PhD
Baylor College of Medicine
Houston, TX
The contribution of the tumor microenvironment to cancer dormancy
J. Javier Bravo-Cordero, PhD
Icahn School of Medicine at Mount Sinai
New York, NY
Effects of age on the tumor microenvironment
Sandra S. McAllister, PhD
Harvard Institutes of Medicine
Boston, MA
Can inflammation be targeted?
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA
|
5:00 pm - 5:15 pm CT |
REFRESHMENT BREAK
|
5:15 pm - 7:15 pm CT |
View from the Trenches: What will You do on Monday Morning - Stars at Night Ballroom 1&2
Moderators: Andrea Barrio, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY
and
Moderator: Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Panel Members
Vernal Branch
Patient Advocate
UNC Chapel Hill Lineberger Cancer Institute
Mooresville, NC
Marianna Chavez- MacGregor, MD, MSC, FASCO
UT MD Anderson Cancer Center
Houston, TX
Tanja N. Fehm, MD
University Hospital
Düsseldorf
Düsseldorf, Germany
Kalliopi
Siziopikou, MD, PhD
Northwestern University
Chicago, IL
Mediget
Teshome, MD, MPH, FACS
UT MD Anderson Cancer Center
Houston, TX
Cynthia
Villareal Garza, MD, DSc
Tecnológico de Monterrey
Monterrey, Mexico
Richard
C. Zellars, MD
Indiana University
Indianapolis, IN
|
Saturday, December 10
8:00 am - 10:00 am |
YEAR IN REVIEW - Hall 3
|
|
Moderators: Carlos Arteaga, MD
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
and
Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Basic science
Andrei Goga, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Translational research
Shom Goel, MBBS, B Med Sci (Hons)
Peter MacCallum Cancer Centre
Melbourne, Australia
Early breast cancer
Marleen Kok, MD, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands
Advanced breast cancer
Melinda Telli, MD
Stanford University School of Medicine
San Francisco, CA
|
|